Claims for Patent: 10,585,106

Summary for Patent: 10,585,106

Title:	Detection and treatment of pregnancy complications comprising determining sialyl Lewis antigens and administering hCG
Abstract:	Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).
Inventor(s):	Sharma; Surendra (Warwick, RI), Kalkunte; Satyan (Frisco, TX), Jeschke; Udo (Munich, DE)
Assignee:	Women & Infants Hospital of Rhode Island (Providence, RI)
Application Number:	15/889,261
Patent Claims:	1. A method of treating incipient preeclampsia in a human female patient-subject, comprising: (a) determining the level of sialyl Lewis antigen X in said patient-subject at about 10 weeks of pregnancy or earlier; (b) determining that said level of sialyl Lewis antigen X of step (a) is at or greater than about 22.4% above a normal control level; and (c) administering to said patient-subject a therapeutically effective amount of human chorionic gonadotropin (hCG); thereby treating the human female patient-subject for incipient preeclampsia. 2. The method of claim 1, further comprising: prior to administering the hCG of step (c), managing said patient-subject for preeclampsia. 3. The method of claim 2, wherein managing said patient-subject comprises determining if the sum of the levels of sialyl Lewis antigen X of step (a) is at or greater than about 30% above the sum of the levels determined in step (b). 4. The method of claim 1, wherein the hCG is recombinant hCG. 5. The method of claim 1, wherein the therapeutically effective amount of hCG is administered intravenously. 6. The method of claim 1, wherein the therapeutically effective amount of hCG is from between about 50 I.U. and about 500 I.U. 7. The method of claim 6, wherein the therapeutically effective amount of hCG is from between about 100 I.U. and about 200 I.U.

Details for Patent 10,585,106

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	10,585,106	2038-02-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	10,585,106	2038-02-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	10,585,106	2038-02-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	10,585,106	2038-02-06
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	10,585,106	2038-02-06
Ferring Pharmaceuticals Inc.	A.P.L.	chorionic gonadotropin	For Injection	017055	December 13, 1974	10,585,106	2038-02-06